[Pharmacokinetic and clinical studies on flomoxef in neonates and premature infants].
Studies were made on pharmacokinetics, clinical effects and influence on intestinal bacterial flora in neonates upon administration of flomoxef (FMOX), and the results obtained are summarized as follows: 1. Serum concentrations of FMOX after intravenous administration of 20 mg/kg/dose were 48.5 micrograms/ml in 30 minutes, 33.0 micrograms/ml in 1 hour and 7.3 micrograms/ml in 6 hours. The T 1/2 was 2.7 hours. FMOX at a dose of 40 mg/kg was given to only one new born baby on the 1st day after birth, and serum concentrations were 73.6 micrograms/ml in 30 minutes, 55.9 micrograms/ml in 1 hour and 16.9 micrograms/ml in 6 hours. The T 1/2 was 4.60 hours. 2. FMOX was administered to 21 neonates between 0 and 32 days of age. Clinical effects were evaluable in 8 of 21 cases. The results were excellent in 2 cases, good in 5 cases and poor in 1 case. Of the 21 cases, diarrhea in 1 case, elevation of eosinophile in 2 cases (9.5%), elevation of platelet count in 3 cases (14.3%), and elevation of GOT in 2 cases (9.5%) were recognized during treatment. 3. FMOX was detected in feces at levels of 0.84-44.4 micrograms/g. Except for a slight decrease in numbers of anaerobes, little fluctuations of intestinal flora were observed during treatment.
Akita
H
H
Department of Pediatrics, Yamato City Hospital.
Sato
Y
Y
Iwata
S
S
Sunakawa
K
K
Yokota
T
T
D001424:Bacterial Infections / Q000188:drug therapy* / Q000378:metabolism / Q000517:prevention & control; D002511:Cephalosporins / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use; D004341:Drug Evaluation; D005260:Female; D006207:Half-Life; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000188:drug therapy* / Q000378:metabolism / Q000517:prevention & control; D007422:Intestines / Q000382:microbiology; D008297:Male
D002511:Cephalosporins; C045693:flomoxef